Impact• Dromedary camels are the only animal species for which there is convincing evidence that it is a host species for MERS-CoV and hence a potential source of human infections.• Direct contact with dromedary camels can only explain a small proportion of the primary cases. Other possible sources and vehicles of infection include food-borne transmission through consumption of unpasteurized camel milk and raw meat, medicinal use of camel urine and zoonotic transmission from other species.• In the Arabian Peninsula, dromedary camel production has intensified and is nowadays concentrated around cities. This may have facilitated the zoonotic 'spillover' infections from camels to humans, explaining the emergence of the virus in the human population in the Arabian Peninsula. SummaryMiddle East respiratory syndrome coronavirus (MERS-CoV) cases without documented contact with another human MERS-CoV case make up 61% (517/853) of all reported cases. These primary cases are of particular interest for understanding the source(s) and route(s) of transmission and for designing long-term disease control measures. Dromedary camels are the only animal species for which there is convincing evidence that it is a host species for MERS-CoV and hence a potential source of human infections. However, only a small proportion of the primary cases have reported contact with camels. Other possible sources and vehicles of infection include food-borne transmission through consumption of unpasteurized camel milk and raw meat, medicinal use of camel urine and zoonotic transmission from other species. There are critical knowledge gaps around this new disease which can only be closed through traditional field epidemiological investigations and studies designed to test hypothesis regarding sources of infection and risk factors for disease. Since the 1960s, there has been a radical change in dromedary camel farming practices in the Arabian Peninsula with an intensification of the production and a concentration of the production around cities. It is possible that the recent intensification of camel herding in the Arabian Peninsula has increased the virus' reproductive number and attack rate in camel herds while the 'urbanization' of camel herding increased the frequency of zoonotic 'spillover' infections from camels to humans. It is reasonable to assume, although difficult to measure, that the sensitivity of public health surveillance to detect previously
In a rapidly changing environment, national institutions in charge of health security can no longer rely only on traditional disease reporting mechanisms that are not designed to recognise emergence of new hazards. Epidemic intelligence provides a conceptual framework within which countries may adapt their public health surveillance system to meet new challenges. Epidemic intelligence (EI) encompasses all activities related to early identification of potential health hazards, their verification, assessment and investigation in order to recommend public health control measures. EI integrates both an indicator-based and an event-based component. ‘Indicator-based component’ refers to structured data collected through routine surveillance systems. ‘Event-based component’ refers to unstructured data gathered from sources of intelligence of any nature. All EU member states have long-established disease surveillance systems that provide proper indicator-based surveillance. For most countries, the challenge lies now in developing and structuring the event-based component of EI within national institution in charge of public health surveillance. In May 2006, the European Union member states committed to comply with provisions of the revised International Health Regulations (IHR(2005)) considered relevant to the risk posed by avian and potential human pandemic influenza. This provides for the European Centre for Disease Prevention and Control (ECDC) with an opportunity to guide member states in developing and/or strengthening their national EI , in addition to the ECDC’s task of developing an EI system for the EU.
Since June 2012, 133 Middle East respiratory syndrome coronavirus (MERS-CoV) cases have been identified in nine countries. Two time periods in 2013 were compared to identify changes in the epidemiology. The case-fatality risk (CFR) is 45% and is decreasing. Men have a higher CFR (52%) and are over-represented among cases. Thirteen out of 14 known primary cases died. The sex-ratio is more balanced in the latter period. Nosocomial transmission was implied in 26% of the cases.
Binary file ES_Abstracts_Final_ECDC.txt matches
Europe has experienced more than two months of the first transmissions and outbreak of the 2009 pandemic of A(H1N1)v. This article summarises some of the experience to date and looks towards the expected autumn increases of influenza activity that will affect every country. To date the distribution of transmission has been highly heterogenous between and within countries, with one country the United Kingdom (UK) experiencing the most cases and the highest transmission rates. Most infections are mild but there are steadily increasing numbers of people needing hospital care and more deaths are being reported. An initial difference in practice between Europe and North America was over case-finding and treatment with some authorities in Europe using active case-finding, contact tracing and treatment/prophylaxis with antivirals to try and delay transmission. This article details the history of this practice in the past two months and explains how and why countries are moving to mitigation, especially treating with antivirals those at higher risk of experiencing severe disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.